Board of directors (12)
Directors with a Section 16 filing in the last 13 months. “Since” is the first filing as a director; SEC data sets start in 2016.
Executive officers (12)
Company facts
- Chair
- Joaquin Duato
- In S&P 500 since
- Jun 1973
- Incorporated in
- NJ
- Fiscal year ends
- January
- SEC industry
- Pharmaceutical Preparations
- SEC filings
- EDGAR
Connections to other S&P 500 companies
Current directors and officers who also hold a role at another S&P 500 company.
- John G. MorikisGIS · DirectorUPS · Director
- Mark A. WeinbergerJPM · DirectorMET · Director
- Daniel E. PintoICE · Director
- Hubert JolySPGI · Director
- Jennifer L. TaubertMCD · Director
- Joseph J. WolkPRU · Director
- Kathryn E. WengelLH · Director
- Marillyn A. HewsonCVX · Director
- Mark B. McClellanCI · Director
- Nadja WestNUE · Director
- Vanessa BroadhurstZTS · Director
Major holders (5% or more)
Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.
No 5% holder filings parsed yet for this company.
Insider trades
Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 2, 2026 | Timothy Schmid EVP, WW Chair, MedTech | Sale | 22,527 | $274.74 | $6.2M |
| Sep 2, 2026 | Timothy Schmid EVP, WW Chair, MedTech | Sale | 11,070 | $274.74 | $3.0M |
| Aug 17, 2026 | Jennifer L. Taubert EVP, WWC. Innovative Medicine | Sale | 15,000 | $263.36 | $4.0M |
| Aug 13, 2026 | Joaquin Duato CEO and Chairman of the Board | Sale | 20,976 | $262.00 | $5.5M |
| Aug 13, 2026 | Joaquin Duato CEO and Chairman of the Board | Sale | 102,315 | $261.00 | $26.7M |
| Aug 6, 2026 | Elizabeth Forminard EVP, Chief Legal Officer | Sale | 6,574 | $255.93 | $1.7M |
| Aug 6, 2026 | Elizabeth Forminard EVP, Chief Legal Officer | Sale | 9,344 | $257.76 | $2.4M |
| Aug 5, 2026 | Joaquin Duato CEO and Chairman of the Board | Sale | 41,957 | $258.06 | $10.8M |
| Aug 5, 2026 | Joaquin Duato CEO and Chairman of the Board | Sale | 6,523 | $258.74 | $1.7M |
| Jul 20, 2026 | Vanessa Broadhurst EVP, Global Corp Affairs | Sale | 23,054 | $251.27 | $5.8M |
| Jun 11, 2026 | Kathryn E. Wengel EVP, Chief TO and Risk Officer | Sale | 10,000 | $241.15 | $2.4M |
| Feb 27, 2026 | Robert J. Decker VP Corporate Controller | Sale | 4,075 | $247.87 | $1.0M |
| Feb 20, 2026 | Timothy Schmid EVP, WW Chair, MedTech | Sale | 1,322 | $245.66 | $325K |
| Feb 18, 2026 | Timothy Schmid EVP, WW Chair, MedTech | Sale | 8,998 | $244.53 | $2.2M |
| Feb 18, 2026 | Timothy Schmid EVP, WW Chair, MedTech | Sale | 13,625 | $244.20 | $3.3M |
| Feb 17, 2026 | James D. Swanson EVP, CIO | Sale | 20,521 | $242.70 | $5.0M |
| Feb 17, 2026 | Joseph J. Wolk Exec VP, CFO | Sale | 19,241 | $242.99 | $4.7M |
| Feb 17, 2026 | Joseph J. Wolk Exec VP, CFO | Sale | 24,961 | $242.68 | $6.1M |
| Feb 17, 2026 | Joseph J. Wolk Exec VP, CFO | Sale | 33,386 | $242.75 | $8.1M |
| Feb 17, 2026 | Joseph J. Wolk Exec VP, CFO | Sale | 12,066 | $242.87 | $2.9M |
| Feb 17, 2026 | John C. Reed EVP, Innovative Medicine, R&D | Sale | 29,927 | $243.00 | $7.3M |
| Feb 17, 2026 | John C. Reed EVP, Innovative Medicine, R&D | Sale | 2,283 | $243.00 | $555K |
| Feb 17, 2026 | John C. Reed EVP, Innovative Medicine, R&D | Sale | 21,721 | $243.00 | $5.3M |
| Feb 17, 2026 | Vanessa Broadhurst EVP, Global Corp Affairs | Sale | 6,197 | $243.39 | $1.5M |
| Feb 13, 2026 | James D. Swanson EVP, CIO | Sale | 19,368 | $243.76 | $4.7M |
Board and executive changes
Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.
- Aug 4, 2026
On August 4, 2026, the Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026. The Company’s related press release is attached to this Report as Exhibit 99.1.
Read the 8-K filing - Sep 9, 2025
On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual. Mr. Morikis will serve on the Audit Committee and Compensation & Benefits Committee. As a non-employee director of the Company, Mr. Morikis will receive compensation as described in the Director Compensation section of the Company’s 2025 Proxy Statement. Mr. Morikis served as the Executive Chairman, President and Chief Executive Officer of The Sherwin-Williams Company from 2016 to 2024. He joined Sherwin-Williams in 1984 as a management trainee in the Paint Stores Group. Over the next four decades, he advanced through key leadership roles, including Division President and Group President. From 2006 to 2016, Mr.
Read the 8-K filing - Jun 10, 2025
On June 10, 2025, Johnson & Johnson (the “Company” or “Johnson & Johnson”) announced that Daniel Pinto was elected to the Board of Directors effective July 1, 2025. Mr. Pinto will serve on the Audit Committee and the Compensation & Benefits Committee. As a non-employee director of the Company, Mr. Pinto will receive compensation as described in the “Director Compensation” section of the Company’s 2025 Proxy Statement. Mr. Pinto currently serves as the President of JPMorganChase and will serve as Vice Chairman of the firm from July 1, 2025 through his retirement at the end of 2026. He previously served as Chief Operating Officer, among other roles, during his tenure at the firm. JPMorganChase provides a variety of banking services to the Company.
Read the 8-K filing - Apr 30, 2025
D. Adamczyk notified the Company that he intends to retire from the Company’s Board of Directors in connection with an announcement on April 23 rd that he will join Goldman Sachs as a Partner. The retirement will be effective May 31, 2025. His retirement is for personal reasons and not as a result of any disagreement with management on any matter relating to the Company’s operations, policies, or practices.
Read the 8-K filing - Sep 10, 2024
On September 10, 2024, D. S. Davis retired as a Director of Johnson & Johnson after the successful transition of Audit Committee Chair responsibilities to D. Adamczyk. His retirement is for personal reasons and not as a result of any disagreement with management on any matter relating to the Company ’ s operations, policies, or practices.
Read the 8-K filing - Aug 26, 2024
On August 26, 2024, Johnson & Johnson (the Company) issued a press release announcing that Peter M. Fasolo, Executive Vice President, Chief Human Resources Officer (CHRO), has elected to retire. He will step down from the role of CHRO and member of the Executive Committee, effective October 1, 2024, and depart the Company at the end of the year. A copy of the Company's press release, dated August 26, 2024, is contained in Exhibit 99.1 to this Report.
Read the 8-K filing - Dec 5, 2023
On November 30, 2023, Johnson & Johnson (the “Company” or “Johnson & Johnson”) announced that Eugene A. Woods, MBA, MHA, was elected to the Board of Directors. As a non-employee director of the Company, Mr. Woods will receive compensation as described in the “Director Compensation” section of the Company’s 2023 Proxy Statement. Mr. Woods is the Chief Executive Officer of Advocate Health. Advocate Health purchases the Company’s medical technologies and pharmaceuticals in the ordinary course of business. During fiscal year 2022, Advocate Health paid the Company approximately $175 million for products used in its hospitals and the Company paid Advocate Health less than $1 million in connection with clinical trials. The Company’s press release announcing the appointment is attached to this Report as Exhibit 99.1.
Read the 8-K filing - Nov 27, 2023
On November 21, 2023, the Compensation & Benefits Committee (the “Committee”) of the Board of Directors of Johnson & Johnson (the “Company”) approved the adoption of the Johnson & Johnson Deferred Compensation Plan (the “Plan”). The Plan is an unfunded, nonqualified deferred compensation plan that provides eligible management and other highly-compensated employees (including named executive officers) with the opportunity to defer, on a pre-tax basis, up to 50% of their base salary and up to 100% of their annual cash performance bonus to be earned in the following year. Participants will be fully vested at all times in their account within the Plan. The Plan does not provide for matching or discretionary Company contributions.
Read the 8-K filing - Oct 23, 2023
On October 23, 2023, the Company announced that Ashley McEvoy resigned from her position as Executive Vice President, Worldwide Chair MedTech and member of the Executive Committee effective October 20, 2023, and will depart the Company in the first quarter of 2024 after a transition period. The Company’s related press release is attached to this Report as Exhibit 99.1.
Read the 8-K filing - May 1, 2023
Upon the closing of the initial public offering of Kenvue Inc., Thibaut Mongon will cease to be Executive Vice President, Worldwide Chairman, Consumer Health and member of the Executive Committee of Johnson & Johnson and will continue his role as Chief Executive Officer of Kenvue Inc.
Read the 8-K filing - Apr 3, 2023
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On March 31, 2023, Ian E. L. Davis retired as a Director of Johnson & Johnson. As disclosed in the Company’s Definitive Proxy Statement filed March 15, 2023, Mr. Davis previously intended to not stand for re-election at the Company’s Annual Shareholder Meeting in keeping with the Company’s refreshment criteria for the Board of Directors. His retirement is for personal reasons and not as a result of any disagreement with management on any matter relating to the Company’s operations, policies, or practices.
Read the 8-K filing - Feb 15, 2023
Johnson & Johnson (the “Company”) announced on February 14, 2023, that Paula A. Johnson, President of Wellesley College, has been appointed to its Board of Directors (the “Board”), effective immediately. Dr. Johnson will serve as a member of the Board’s Nominating & Corporate Governance Committee, effective as of April 27, 2023. As a non-employee Director of the Company, Dr. Johnson will receive compensation as described in the “Director Compensation” section of the Company's 2023 Proxy Statement. The Company’s press release announcing the appointment is attached to this Report as Exhibit 99.1.
Read the 8-K filing - Feb 14, 2023
Johnson & Johnson (the “Company”) announced on February 14, 2023, that Paula A. Johnson, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the “Board”), effective immediately. Ms. Johnson will serve as a member of the Board’s Nominating & Corporate Governance Committee, effective as of April 27, 2023. As a non-employee Director of the Company, Ms. Johnson will receive compensation as described in the “Director Compensation” section of the Company's 2023 Proxy Statement. The Company’s press release announcing the appointment is attached to this Report as Exhibit 99.1.
Read the 8-K filing - Dec 1, 2022
On November 30, 2022, the Company announced that its Board of Directors elected Joaquin Duato Chairman, Board of Directors of Johnson & Johnson effective upon current Chairman Alex Gorsky’s retirement from the Board of Directors. Mr. Duato was appointed Chief Executive Officer of the Company in January 2022. Current Chairman Alex Gorsky will step down from the Board in January 2023, following a brief transition period and will not stand for reelection in 2023. The Company’s related press release is attached to this Report as Exhibit 99.1.
Read the 8-K filing - Apr 29, 2022
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing
Show 9 older changes
- Feb 16, 2022
Johnson & Johnson (the “Company”) announced on February 15, 2022, that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the “Board”), effective immediately. Mr. Adamczyk will serve as a member of the Board’s Audit Committee and Compensation & Benefits Committee, effective as of April 28, 2022. As a non-employee Director of the Company, Mr. Adamczyk will receive compensation as described in the “Director Compensation” section of the Company's 2022 Proxy Statement. The Company’s press release announcing the appointment is attached to this Report as Exhibit 99.1.
Read the 8-K filing - Jan 6, 2022
As previously announced by Johnson & Johnson (the “Company”) on August 19, 2021, effective as of January 3, 2022, Joaquin Duato, previously Vice Chairman of the Company’s Executive Committee, assumed the role of Chief Executive Officer (“CEO”) of the Company and has been appointed as a member of the Company’s Board of Directors (the “Board”). Alex Gorsky, previously Chairman and CEO of the Company, transitioned to Executive Chairman of the Company, also effective January 3, 2022. On January 4, 2022, the Board approved compensation changes for Mr. Duato and Mr. Gorsky in conjunction with their respective role changes. Upon his assumption of the CEO role, Mr.
Read the 8-K filing - Oct 12, 2021
On October 12, 2021, Johnson & Johnson (the “Company”) issued a press release announcing that Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, has elected to retire, effective December 31, 2021. A copy of the Company's press release, dated October 12, 2021, is contained in Exhibit 99.1 to this Report.
Read the 8-K filing - Aug 20, 2021
On August 19, 2021, the Board of Directors (the “Board”) of Johnson & Johnson (the “Company”) decided: • Alex Gorsky, currently Chairman and Chief Executive Officer (“CEO”) of the Company, will relinquish the CEO position, effective January 3, 2022, and will continue his service on the Board as Executive Chairman. • Joaquin Duato will become CEO of the Company, effective January 3, 2022; • Mr. Duato will be appointed a Director of the Board, effective January 3, 2022; and A copy of the Company's press release, dated August 19, 2021, to announce these decisions is contained in Exhibit 99 to this Report. Mr. Duato, age 59, is currently Vice Chairman of the Company's Executive Committee and provides strategic direction for the Pharmaceutical and Consumer Health sectors and oversees the Global Supply Chain, Technology and Health & Wellness teams. Mr.
Read the 8-K filing - Dec 3, 2020
Johnson & Johnson (the "Company") announced on December 3, 2020, that Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General, has been appointed to its Board of Directors (the "Board"), effective immediately. Dr. West will serve as a member of the Board’s Science, Technology & Sustainability Committee, effective as of January 1, 2021. As a non-employee Director of the Company, Dr. West will receive compensation as described in the “Director Compensation” section of the Company's 2020 Proxy Statement. The Company's press release announcing the appointment is attached to this Report as Exhibit 99.1.
Read the 8-K filing - Dec 5, 2019
Johnson & Johnson (the "Company") announced on December 5, 2019, that Hubert Joly, Executive Chairman of Best Buy Co., Inc., and Mark A. Weinberger, former EY Global Chairman and CEO, have been appointed to its Board of Directors (the "Board"), effective immediately. Mr. Joly will serve as a member of the Board’s Nominating & Corporate Governance Committee, and Mr. Weinberger will serve as a member of the Board's Audit Committee and Regulatory Compliance Committee, effective as of January 1, 2020. As non-employee Directors of the Company, Messrs. Joly and Weinberger will receive compensation as described in the “Director Compensation” section of the Company's 2019 Proxy Statement. The Company's press release announcing the appointments is attached to this Report as Exhibit 99.1.
Read the 8-K filing - Oct 7, 2019
On October 7, 2019, Johnson & Johnson (the “Company”) announced that Ronald A. Kapusta, Controller and Chief Accounting Officer, has elected to retire, effective December 27, 2019. Robert J. Decker, Jr. has been appointed Controller and Chief Accounting Officer of the Company, effective December 27, 2019. Mr. Decker, 47, joined the Company in June 1993 and held a number of positions of increasing responsibility within the Company’s Consumer, Pharmaceutical, Medical Devices and Corporate divisions before being named to his current role as Assistant Corporate Controller in August 2017. In his role prior to Assistant Corporate Controller, Mr. Decker was the Chief Financial Officer (CFO), North America Medical Devices from 2015 through 2017. Prior to that, Mr.
Read the 8-K filing - Jun 22, 2018
As previously announced, Joseph Wolk has been promoted to Executive Vice President, Chief Financial Officer of Johnson & Johnson (the “Company”), and a Member of the Executive Committee, effective July 1, 2018. Mr. Wolk succeeds Dominic J. Caruso, Executive Vice President, Chief Financial Officer, who, as previously announced, elected to retire in September 2018 after a distinguished 19-year career with the Company. Mr. Wolk, 52, has been with Johnson & Johnson since 1998 and currently serves as Vice President, Investor Relations. Mr. Wolk began his career with the Finance department where he held positions of increasing responsibility across the Pharmaceutical and Medical Device sectors, including most recently: Vice President, Finance Medical Device Supply Chain from April 2010 to June 2014; and Vice President, Finance, Pharmaceuticals until July 2016.
Read the 8-K filing - Mar 20, 2018
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements for Certain Officers. On March 20, 2018, the Company issued a press release announcing that Dominic J. Caruso, the Company's Executive Vice President, Chief Financial Officer, has elected to retire in September 2018. The Company also announced that Joseph Wolk, Vice President of Investor Relations for Johnson & Johnson, has been appointed Executive Vice President, Chief Financial Officer, effective July 1, 2018. Mr. Wolk will report to Alex Gorsky, the Company's Chairman and Chief Executive Officer, and become a member of the Company's Executive Committee. Mr. Wolk, 51, has led the Investor Relations organization since August 2016. Previously, he was Vice President, Group Finance for the Pharmaceuticals Group and a member of the Pharmaceuticals Group Operating Committee. In 2010, Mr.
Read the 8-K filing
Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021
Share price
Annual financials
From the company's 10-K XBRL data (SEC companyfacts).
| Fiscal year | Revenue | Net income | Margin | Diluted EPS | Total assets |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | 28.5% | $11.03 | $199.2B |
| FY2024 | $88.8B | $14.1B | 15.8% | $5.79 | $180.1B |
| FY2023 | $85.2B | $35.2B | 41.3% | $13.72 | $167.6B |
| FY2022 | $80.0B | $17.9B | 22.4% | $6.73 | $187.4B |
| FY2021 | $78.7B | $20.9B | 26.5% | $7.81 | $182.0B |
| FY2020 | $82.6B | $14.7B | 17.8% | $5.51 | $174.9B |
| FY2019 | $82.1B | $15.1B | 18.4% | $5.63 | $157.7B |
| FY2018 | $81.6B | $15.3B | 18.8% | $5.61 | $153.0B |
Former directors and officers (24)
People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.